

GLAXOSMITHKLINE PLC

Form 6-K

August 10, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 10 August 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.9292	8 (partnership shares)
£15.9292	8 (matching shares)
  - d) Aggregated information
 

Aggregated information	16 Ordinary Shares
Aggregated volume Price	£15.9292
  - e) Date of the transaction 2018-08-09
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

place where transaction(s) has been conducted

- |  |   |
|--|---|
| a) Description of the financial instrument | Ordinary shares of 25 pence each<br>(‘Ordinary Shares’)<br>ISIN: GB0009252882         |
| b) Nature of the transaction               | Acquisition of Ordinary Shares<br>under the Company's Share<br>Reward Plan.           |
| c) Price(s) and volume(s)                  | Price(s) Volume(s)<br>£15.9292 8 (partnership shares)<br>£15.9292 8 (matching shares) |
| d) Aggregated information                  | 16 Ordinary Shares  |
| Aggregated volume Price                    | £15.9292  |
| e) Date of the transaction                 | 2018-08-09  |
| f) Place of the transaction                | London Stock Exchange (XLON)  |

1. Details of PDMR/person closely associated with them (‘PCA’)

- |                                       |                         |
|---------------------------------------|-------------------------|
| a) Name                               | Mr S Dingemans          |
| b) Position/status                    | Chief Financial Officer |
| c) Initial notification/<br>amendment | Initial notification    |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |  |   |
|--|---|
| a) Description of the financial instrument | Ordinary shares of 25 pence each<br>(‘Ordinary Shares’)<br>ISIN: GB0009252882         |
| b) Nature of the transaction               | Acquisition of Ordinary Shares<br>under the Company's Share<br>Reward Plan.           |
| c) Price(s) and volume(s)                  | Price(s) Volume(s)<br>£15.9292 8 (partnership shares)<br>£15.9292 8 (matching shares) |
| d) Aggregated information                  | 16 Ordinary Shares  |
| Aggregated volume Price                    | £15.9292  |

- e) Date of the transaction 2018-08-09  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics & Compliance  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £15.9292 8 (partnership shares)  
 £15.9292 8 (matching shares)

- d) Aggregated information 16 Ordinary Shares  
 Aggregated volume Price £15.9292

- e) Date of the transaction 2018-08-09  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Miels  
 b) Position/status President, Global Pharmaceuticals  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

place where transaction(s) has been conducted

- |  |  |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882                     |
| b) Nature of the transaction               | Acquisition of Ordinary Shares under the Company's Share Reward Plan.                          |
| c) Price(s) and volume(s)                  | Price(s)    Volume(s)<br>£15.9292    8 (partnership shares)<br>£15.9292    8 (matching shares) |
| d) Aggregated information                  | 16 Ordinary Shares   |
| Aggregated volume Price                    | £15.9292   |
| e) Date of the transaction                 | 2018-08-09   |
| f) Place of the transaction                | London Stock Exchange (XLON)   |

1. Details of PDMR/person closely associated with them ('PCA')

- |                                       |                        |
|---------------------------------------|------------------------|
| a) Name                               | Mr D S Redfern         |
| b) Position/status                    | Chief Strategy Officer |
| c) Initial notification/<br>amendment | Initial notification   |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |  |  |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882                     |
| b) Nature of the transaction               | Acquisition of Ordinary Shares under the Company's Share Reward Plan.                          |
| c) Price(s) and volume(s)                  | Price(s)    Volume(s)<br>£15.9292    8 (partnership shares)<br>£15.9292    8 (matching shares) |
| d) Aggregated information                  | 16 Ordinary Shares   |
| Aggregated volume Price                    | £15.9292   |

e) Date of the transaction 2018-08-09  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas  
 b) Position/status SVP, Human Resources  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £15.9292 8 (partnership shares)  
 £15.9292 8 (matching shares)

d) Aggregated information  
 Aggregated volume Price 16 Ordinary Shares  
 £15.9292

e) Date of the transaction 2018-08-09  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson  
 b) Position/status President, Global Affairs  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s)              |
|----------|------------------------|
| £15.9292 | 8 (partnership shares) |
| £15.9292 | 8 (matching shares)    |
- d) Aggregated information
- | Aggregated volume  | Price    |
|--------------------|----------|
| 16 Ordinary Shares | £15.9292 |
- e) Date of the transaction 2018-08-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s)              |
|----------|------------------------|
| £15.9292 | 8 (partnership shares) |
| £15.9292 | 8 (matching shares)    |
- d) Aggregated information

Aggregated volume Price	16 Ordinary Shares £15.9292
-------------------------	--------------------------------

e) Date of the transaction	2018-08-09
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: August 10, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc